ZA201208389B - Treatment of proliferative diseases - Google Patents
Treatment of proliferative diseasesInfo
- Publication number
- ZA201208389B ZA201208389B ZA2012/08389A ZA201208389A ZA201208389B ZA 201208389 B ZA201208389 B ZA 201208389B ZA 2012/08389 A ZA2012/08389 A ZA 2012/08389A ZA 201208389 A ZA201208389 A ZA 201208389A ZA 201208389 B ZA201208389 B ZA 201208389B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- proliferative diseases
- proliferative
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35812610P | 2010-06-24 | 2010-06-24 | |
| PCT/AU2011/000760 WO2011160174A1 (en) | 2010-06-24 | 2011-06-23 | Treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201208389B true ZA201208389B (en) | 2013-06-26 |
Family
ID=45370753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/08389A ZA201208389B (en) | 2010-06-24 | 2012-11-08 | Treatment of proliferative diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120172313A1 (enExample) |
| EP (1) | EP2585095A4 (enExample) |
| JP (1) | JP2013530965A (enExample) |
| KR (1) | KR20140003316A (enExample) |
| CN (1) | CN103037888A (enExample) |
| AU (1) | AU2011269726B2 (enExample) |
| CA (1) | CA2803027A1 (enExample) |
| MX (1) | MX2012014711A (enExample) |
| NZ (1) | NZ603442A (enExample) |
| SG (1) | SG186385A1 (enExample) |
| WO (1) | WO2011160174A1 (enExample) |
| ZA (1) | ZA201208389B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101951057B1 (ko) | 2011-02-07 | 2019-02-21 | 헥시마 리미티드 | 항병원성 물질로서 유용한 변경된 식물 데펜신 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3384938A1 (en) * | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012325676B2 (en) | 2011-10-19 | 2016-07-21 | Balmoral Australia Pty Ltd | Novel plant defensins and use in the treatment of proliferative diseases |
| EP3303376A4 (en) * | 2015-05-29 | 2019-01-23 | Hexima Limited | IN VIVO METHOD |
| CN111751345A (zh) * | 2020-07-08 | 2020-10-09 | 深圳海关动植物检验检疫技术中心 | 一种苜蓿黄萎病菌活性检测方法 |
| KR102371762B1 (ko) * | 2020-12-29 | 2022-03-07 | 중앙대학교 산학협력단 | Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1339849B1 (en) * | 2000-08-25 | 2006-10-18 | BASF Plant Science GmbH | PLANT POLYNUCLEOTIDES ENCODING NOVEL Na+ /H+ ANTIPORTERS |
| CN101029308B (zh) * | 2001-02-08 | 2012-07-25 | 赫希玛有限公司 | 植物来源分子、其编码遗传序列及其用途 |
| US20070207209A1 (en) * | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| BRPI0916867A2 (pt) * | 2008-08-05 | 2017-05-23 | Hexima Ltd | métodos para proteger uma planta de uma doença associada com infecção por um patógeno, e para identificar uma defensiva, uso de uma defensina de planta e um inibidor de proteinase ou uma forma precursora, planta geneticamente modificada ou progênie desta, e, defensiva |
-
2011
- 2011-06-23 SG SG2012093050A patent/SG186385A1/en unknown
- 2011-06-23 US US13/166,960 patent/US20120172313A1/en not_active Abandoned
- 2011-06-23 CN CN2011800312370A patent/CN103037888A/zh active Pending
- 2011-06-23 KR KR1020127032033A patent/KR20140003316A/ko not_active Withdrawn
- 2011-06-23 MX MX2012014711A patent/MX2012014711A/es unknown
- 2011-06-23 EP EP11797388.3A patent/EP2585095A4/en not_active Withdrawn
- 2011-06-23 JP JP2013515634A patent/JP2013530965A/ja active Pending
- 2011-06-23 AU AU2011269726A patent/AU2011269726B2/en not_active Ceased
- 2011-06-23 NZ NZ603442A patent/NZ603442A/xx not_active IP Right Cessation
- 2011-06-23 CA CA2803027A patent/CA2803027A1/en not_active Abandoned
- 2011-06-23 WO PCT/AU2011/000760 patent/WO2011160174A1/en not_active Ceased
-
2012
- 2012-11-08 ZA ZA2012/08389A patent/ZA201208389B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140003316A (ko) | 2014-01-09 |
| AU2011269726A1 (en) | 2012-11-29 |
| AU2011269726B2 (en) | 2013-11-28 |
| MX2012014711A (es) | 2013-03-21 |
| US20120172313A1 (en) | 2012-07-05 |
| SG186385A1 (en) | 2013-01-30 |
| EP2585095A4 (en) | 2013-11-13 |
| CN103037888A (zh) | 2013-04-10 |
| NZ603442A (en) | 2013-09-27 |
| JP2013530965A (ja) | 2013-08-01 |
| EP2585095A1 (en) | 2013-05-01 |
| WO2011160174A1 (en) | 2011-12-29 |
| CA2803027A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269808A (en) | Combined treatment methods for the treatment of proliferative diseases | |
| ZA201301601B (en) | Treatment of diseases | |
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| ZA201207357B (en) | Pyrrolobenzodiazepines used to treat proliferative diseases | |
| IL232530A0 (en) | Combined cancer treatment | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| PT2429524T (pt) | Formulação de ac220 seca por atomização | |
| EP2585828A4 (en) | METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES | |
| IL228430A0 (en) | Cancer treatment | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| IL256026B (en) | Treatment methods | |
| EP2585095A4 (en) | TREATMENT OF PROLIFERATIVE DISEASES | |
| HUP1100290A2 (en) | Combination compositions for the treatment of proliferative diseases | |
| GB201107467D0 (en) | Novel treatment of pain | |
| ZA201103007B (en) | Treatment of tantalium-and/or niobium-containing compounds | |
| GB201010638D0 (en) | Composition for treatment of skin | |
| HK1178089A (en) | Treatment of proliferative diseases | |
| GB201002500D0 (en) | Treatment of burns | |
| EG26997A (en) | Tube for treatment of syrngomylia | |
| ZA201008686B (en) | Treatment of animals | |
| GB201017354D0 (en) | Treatment of cancer | |
| AU2011902407A0 (en) | Treatment of pain | |
| GB201121783D0 (en) | Treatment of cancer | |
| GB201014736D0 (en) | Treatment of hepatitis C |